Previous Article | Next Article 
Journal of Virology, October 2000, p. 9106-9114, Vol. 74, No. 19
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Herpes Simplex Virus Types 1 and 2 Differ in Their
Interaction with Heparan Sulfate
Edward
Trybala,
Jan-Åke
Liljeqvist,
Bo
Svennerholm, and
Tomas
Bergström*
Department of Clinical Virology, University
of Göteborg, S-413 46 Göteborg, Sweden
Received 28 February 2000/Accepted 13 July 2000
 |
ABSTRACT |
Cell surface heparan sulfate (HS) serves as an initial receptor for
many different viruses, including herpes simplex virus types 1 and 2 (HSV-1 and 2, respectively). Glycoproteins C and B (gC and gB) are
the major components of the viral envelope that mediate
binding to HS. In this study, purified gB and gC homologous proteins as well as purified HSV-1 and HSV-2 virions were compared for
the ability to bind isolated HS receptor molecules. HSV-1 gC and HSV-2
gC bound comparable amounts of HS. Similarly, HSV-1 gB and its HSV-2
counterpart showed no difference in the HS-binding capabilities.
Despite the similar HS-binding potentials of gB and gC homologs, HSV-1
virions bound more HS than HSV-2 particles. Purified gC and gB proteins
differed with respect to sensitivity of their interaction with HS to
increased concentrations of sodium chloride in the order gB-2 > gB-1 > gC-1 > gC-2. The corresponding pattern for binding
of whole HSV virions to cells in the presence of increased ionic
strength of the medium was HSV-2 gC-neg1 > HSV-1
gC
39 > HSV-1 KOS 321 > HSV-2 333. These
results relate the HS-binding activities of individual glycoproteins
with the cell-binding abilities of whole virus particles. In addition,
these data suggest a greater contribution of electrostatic forces for
binding of gB proteins and gC-negative mutants compared with binding of
gC homologs and wild-type HSV strains. Binding of wild-type HSV-2
virions was the least sensitive to increased ionic strength of the
medium, suggesting that the less extensive binding of HS molecules by HSV-2 than by HSV-1 can be compensated for by a relatively weak contribution of electrostatic forces to the binding. Furthermore, gB
and gC homologs exhibited different patterns of sensitivity of binding
to cells to inhibition with selectively N-, 2-O-, and 6-O-desulfated
heparin compounds. The O-sulfate groups of heparin were found to be
more important for interaction with gB-1 than gB-2. These results
indicate that HSV-1 and HSV-2 differ in their interaction with HS.
 |
INTRODUCTION |
Cell surface carbohydrate moieties
frequently serve as initial receptors for viruses. Their location at
the cell periphery and their abundant expression, ubiquity, and
frequency of negative charge load make them well suited for
electrostatic attraction of viruses to the cell membrane. This event is
followed by an initial weak virus-cell contact that concludes in
multiple interactions between numerous copies of the viral attachment
proteins and receptor molecules. Such a cascade of events is of
great importance in the stable cell adherence of complex pathogens such
as enveloped viruses. One example of a viral receptor of carbohydrate
nature is heparan sulfate (HS) proteoglycan, the molecule first
identified to serve as initial receptor for herpes simplex virus types
1 and 2 (HSV-1 and -2) by WuDunn and Spear (52). At least
two proteins of both HSV-1 and HSV-2 envelope, glycoprotein C
(designated gC-1 for HSV-1 and gC-2 for HSV-2) and glycoprotein B
(gB-1 and gB-2, respectively), were demonstrated to be able to bind
heparin (10, 14, 49), a molecule related to HS. It has been
reported that in HSV-1, gC-1 played a key role in the adsorption of
wild-type HSV-1 to cells (14), whereas gB-1 mediated binding
of gC-null mutants (15). In contrast, gC-2 was not found to
be a key attachment protein of HSV-2, and consequently a greater
contribution of gB for HSV-2 than HSV-1 binding has been suggested
(10). In addition to providing sites for initial virus
binding, HS was reported to promote HSV-1-induced cell-to-cell fusion
(42). Furthermore, HS modified by 3-O-sulfotransferase
isomer 3 was recently reported to be able to interact with HSV-1 gD, an
event that triggered the virus entry into cell (43).
Although both HSV-1 and HSV-2 target HS as a receptor molecule, these
viruses have been reported to exhibit a number of type-specific differences in their interactions with host cells. In particular, HSV-2
infection of cells was more efficiently inhibited than that of HSV-1 by
polyanionic substances such as heparin, dextran sulfate, agar
inhibitors, and chondroitin sulfate B (19). In contrast, polycationic substances such as neomycin and poly-L-lysine
more efficiently inhibited infection by HSV-1 than by HSV-2 strains (24, 25), and this phenotype was mapped to the N-terminal region of gC-2 (2, 26, 37). Moreover, HSV-2 exhibited
greater sensitivity than HSV-1 as regards inhibition of viral binding by O-desulfated heparins, a type-specific phenotype that was
attributed to gC-2 (13). Furthermore, HSV-1 but not HSV-2
infection of mutant HS- and chondroitin sulfate-deficient cells was
stimulated by dextran sulfate, and it was demonstrated that gB-1
mediated this ability whereas the presence of gC-2 exerted an
inhibitory effect (5). Finally, HSV-1-infected but not
HSV-2-infected cells bound the C3b component of complement, and gC-1
was identified to act as a receptor for C3b (8).
Interestingly, whereas HSV-2-infected cells bound no C3b, purified gC-2
exhibited such activity (6, 34), indicating that differences
in the presentation and/or quantity of gC-1 and gC-2 on virus-infected
cells or on the virion surface may account for type-specific phenotypes
with respect to C3b binding and sensitivity to polyanionic and
polycationic substances.
The carbohydrate moieties of HS proteoglycans, i.e., HS chains, provide
receptor sites for HSV, and a single chain may contain up to several
hundred saccharides. For example, HS chains that occur in green monkey
kidney (GMK AH1) and human epidermoid carcinoma (HEp-2) cells averaged
30 kDa (7) and 105 kDa (33) in apparent molecular
mass, which correspond to approximately 55 nm (120 sugar residues per
chain) and 190 nm (420 sugar residues), respectively, in chain length.
Simple calculation indicates that HEp-2 cell-specific HS could
theoretically adhere to almost half of the virion circumference. HS
chains are composed of alternating glucosamine and uronic acid residues. These sugar residues can be modified by N-, 6-O-,
and 3-O-sulfation (glucosamine) and by 2-O-sulfation (uronic acid). In
contrast to heparin, which could be described as a continuous block of
extensively sulfated saccharides, there is a nonuniform distribution of
sulfate groups in HS, with an overall tendency to form clusters.
Consequently, HS chains are thought to possess a domain-like structure
where blocks of weakly sulfated saccharides alternate with stretches of
moderately to highly sulfated sugar residues (for a review, see
reference 40). According to the protein-polyelectrolyte interaction theory (32), the binding of protein to HS relies on the release of cations, most notably sodium
ions, from polyanionic HS chains by positively charged components of
the protein. The protein-HS complexes can dissociate at specific ionic
strength of the medium, and the HS-binding proteins significantly
differ with regard to this parameter. An overall tendency is that the
higher the concentration of sodium ions necessary to break the
protein-HS complex, the lower the contribution of electrostatic forces
for the binding. For example, for the interaction of fibroblast growth
factor with heparin that dissociates in the presence of more than 1 M
NaCl, it was shown that only approximately 30% of the binding energy
resulted from pure electrostatic forces (50). However, most
of the proteins elute from heparin/HS chains at relatively low ionic
strength of the medium, and the contribution of electrostatic forces to
their binding is significant.
In this investigation, we compared purified gB and gC homologs as well
as whole HSV virions for the ability to bind isolated HS receptor
molecules. Our results revealed that HSV-2 virions bound less HS than
did HSV-1 particles, but the contribution of relatively nonspecific
electrostatic forces was greater for HSV-1 than for HSV-2 binding to cells.
 |
MATERIALS AND METHODS |
Cells and viruses.
African green monkey kidney (GMK AH1)
cells were cultivated in Eagle's minimum essential medium (EMEM)
supplemented with 2% calf serum, 0.05% Primaton RT substance, and
antibiotics. Baby hamster kidney (BHK) cells were propagated in Glasgow
minimum essential medium supplemented with 8% calf serum, 8% tryptose phosphate broth, 1 mM L-glutamine, and antibiotics. Human
epidermoid carcinoma (HEp-2) cells were grown in EMEM supplemented with
8% fetal bovine serum. The HSV strains used were HSV-1 KOS 321, a plaque-purified isolate of wild-type strain KOS (17), an
HSV-1 KOS gC-null mutant designated gC
39 (16),
HSV-2 strain 333 (4), and a local clinical isolate of HSV-2
designated B4327UR (22). The former three strains were kindly provided by J. Glorioso (University of Pittsburgh School of
Medicine, Pittsburgh, Pa.). The gB and gC genes of strains KOS 321 and
333 have been sequenced (18, 38, 46, 48). For the B4327UR
isolate, the coding sequence for gC-2 is available (EMBL database,
accession number AJ297389). For preparation of the HSV-2 gC-negative
mutant, plaques produced by HSV-2 333 were immunostained by using
rabbit polyclonal anti-gC sera R65 and R118 (a generous gift from G. Cohen and R. Eisenberg, University of Pennsylvania, Philadelphia), and
then several unstained plaques were selected for purification to the
point of homogeneity. One clone, designated HSV-2 gC-neg1, was
sequenced by PCR and appeared to carry a frameshift mutation, due to an
insertion of cytosine within a run of five cytosines that precedes
codon 166. This alteration gave rise to a stop codon at triplet 252 resulting in a premature truncation of gC-2.
Virus purification.
The virus was purified from infectious
culture media of GMK AH1 cells. For preparation of radiolabeled virus,
the cells were infected at an multiplicity of infection of 3 PFU per
cell; after an adsorption period of 2 h at 37°C, the cells were
washed and then incubated for 48 h at 37°C in EMEM supplemented
with [methyl-3H]thymidine (25 µCi/ml). The
media were clarified by centrifugation at 1,000 × g
for 25 min and then by centrifugation at 5,000 × g for
10 min. Extracellular virus was pelleted from the resulting supernatant
by centrifugation at 22,000 × g for 2 h. The
pellet was covered with phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM
KH2PO4) and left overnight at 4°C. The virus
was purified from the pelleted material by centrifugation through a
three-step discontinuous sucrose gradient (23). The relative
number of virions in purified HSV-1 and HSV-2 preparations was
determined by quantitating amounts of the major viral capsid protein
(VP5) as described by WuDunn and Spear (52). Briefly, serial
twofold dilutions of purified virions were electrophoresed under
reducing conditions on a 4 to 12% NuPAGE Bis-Tris precast gel and
stained with colloidal blue kit as instructed by the manufacturer (Novex, San Diego, Calif.). Relative amounts of VP5 were determined by
comparing the densities of the stained proteins.
Purification of viral glycoproteins.
Confluent monolayers of
GMK AH1 cells (for gC-1, gB-1, and gB-2 purification) or BHK and HEp-2
cells (for gC-2 purification) in roller bottles were infected with
strain KOS 321 or B4327UR; when the cytopathic effect was pronounced,
the cells and media were harvested. The virus was spun down from the
media by centrifugation at 130,000 × g for 1 h,
and both the virus pellet and infected cells were stored at
70°C.
The infected cells and/or viral pellet were lysed with cold 0.02 M
Tris-HCl buffer (pH 7.5) containing 1% sodium deoxycholate, 1%
Nonidet P-40, 2 mM EDTA, 2 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride, and 2 mM
N
-p-tosyl-L-lysine chloromethyl
ketone. The mixture was dispersed vigorously with a pipette and left on
ice for 1 h. Unsolubilized material was pelleted by centrifugation at 130,000 × g for 1 h; the supernatant was
preadsorbed on an immunosorbent column containing anti-gE monoclonal
antibody B1E6 (to prevent possible contamination of gC preparations
with gE) and then passed through columns containing monoclonal antibody C4H11 (anti-gC-1) or B11D8 (anti-gB) (1). For purification of gC-2, rabbit anti-HSV gC polyclonal serum K65 was used to prepare an
immunosorbent column (6). Subsequently the columns were washed with 0.02 M Tris-HCl (pH 7.5) containing 0.1% Nonidet P-40, 0.5 M NaCl, and 2 mM EDTA. To minimize the amount of detergent in purified
viral proteins, the columns were washed with detergent-free washing
buffer just before elution with 0.1 M glycine-HCl (pH 2.4). Following
neutralization of the eluent with 1 M Tris-HCl (pH 8.0), the material
was centrifuged to near dryness over a microcentrifugal concentrator
with a 30-kDa cutoff (PallGelman Sciences, Lund, Sweden), then
resuspended in PBS, and centrifuged again. The final product was
suspended in a small volume of PBS and stored at
70°C. Protein
concentration was determined according to standard Lowry method (DC
protein assay kit; Bio-Rad).
Isolation of HS chains.
Nearly confluent monolayers of HEp-2
or GMK AH1 cells were labeled for 48 h with
N235SO4 (50 µCi/ml; specific
activity, 1,325 Ci/mmol; NEN Life Science Products, Boston, Mass.) in
low-sulfate EMEM (10% original sulfate concentration) supplemented
with 10% fetal calf serum and antibiotics. Cell-associated HS chains
were purified by the method of Lyon et al. (30).
Modified heparin compounds.
Modifications were performed on
bovine lung heparin which had been isolated and purified as previously
described (27). Selective 2-O-desulfation was
performed by lyophilization at pH 12.5 as previously described
(21). N-desulfation was performed on the pyridiminium salt
of heparin in dimethyl sulfoxide-H2O (19:1) at 50°C for
90 min (20). Preferential 6-O-desulfation was performed in
dimethyl sulfoxide-methanol (9:1) at 93°C for 2 h
(35). O-desulfated heparin chains were N-resulfated
(28), whereas N-desulfated heparin was N-acetylated
(3).
Neuraminidase and glycosidase treatment.
Five-microgram
aliquots of purified gC-1 and gC-2 in 0.1 M sodium phosphate buffer (pH
7.3) were treated for 2 h at 36°C with 5 mU of neuraminidase, 5 mU of both neuraminidase and O-glycosidase, and 250 mU of
endoglycosidase F/N-glycosidase F (all enzymes from Boehringer Mannheim
Scandinavia AB, Bromma, Sweden). Products of mock and enzymatic
digestions were subjected to electrophoresis under reducing conditions
on a 10% acrylamide tris-glycine precast gel and then stained with a
colloidal blue kit (Novex). Purified HSV-1 and HSV-2 in 0.2 ml of PBS
were incubated with 20 mU of neuraminidase for 1 h at 36°C.
Binding of glycosaminoglycans to HSV proteins and HSV
virions.
Equal quantities of purified gB and gC proteins (adjusted
according to protein contents) or the same relative number of HSV-1 and
HSV-2 particles (quantification based on relative amounts of the VP5
protein) were diluted in 0.2 ml of PBS supplemented with 0.05% bovine
serum albumin (PBS-BSA) and then mixed with ca. 5,000 cpm of GMK AH1 or
HEp-2 cell-specific 35S-HS. Following incubation for 2 h at room temperature, the amounts of bound glycosaminoglycan were
determined by the nitrocellulose membrane filtration method
(31). The binding of viral proteins to HS in the presence of
increased concentrations of sodium chloride was assayed in a similar
manner, except that the protein-HS mixtures were incubated in phosphate
buffer in which the concentration of sodium chloride was adjusted to
required values with a 2 M solution of sodium chloride in phosphate buffer.
Viral plaque assay in the presence of modified heparin
compounds.
Serial fivefold dilutions of a specific compound in 2 ml of cold Hanks balanced salt solution (without phenol red and
glucose) was mixed with 200 µl of the same medium containing ca. 200 PFU of either HSV-1 or HSV-2 and incubated for 10 min at 4°C (cold room). Confluent, dense monolayers (3 days old) of GMK AH1 cells in
six-well plates, precooled for 20 min at room temperature and for 20 min at 4°C, were washed with 2 ml of cold Hanks medium; then 1-ml
portions of the virus-heparin mixture were added. Following adsorption
for 1 h at 4°C, the cells were washed twice with 2 ml of cold
Hanks medium and overlaid with 4 ml of EMEM containing 1%
methylcellulose, 2% fetal calf serum, and antibiotics. The plaques
were stained with crystal violet solution after 3 days of incubation at
37°C. In a set of similar experiments, incubation of the
virus-heparin mixture in EMEM and subsequent virus adsorption to cells
were carried out at 37°C. The concentrations of heparin preparations
that inhibited the number of viral plaques by 50% (IC50s)
were interpolated from the dose-response curves.
Binding of purified viral proteins to cells in the presence of
modified heparin compounds.
The effect of selectively or
preferentially N-, 2-O-, or 6-O-desulfated heparin preparations on
binding of purified gC-1, gC-2, gB-1, and gB-2 to GMK AH1 cells was
tested by an enzyme-linked immunosorbent assay (ELISA)-attachment
method as described previously (29, 47). Both preincubation
of glycoproteins with heparin compounds and their attachment to GMK AH1
cells were carried out at 4°C.
Enzymatic digestion of cells.
Confluent monolayers of
3-day-old GMK AH1 cells in six-well plates were washed twice with 2 ml
of Hanks medium, and 1-ml portions of the same medium containing
various numbers of heparinase units were added. Following incubation at
37°C for 1 h and at 4°C for 20 min, the cells were washed
twice with 2 ml of cold Hanks medium, and ca. 200 PFU of the virus in 1 ml of Hanks medium was added. Following virus adsorption for 1 h
at 4°C, the cells were washed twice with 2 ml of Hanks medium and
overlaid with 3 ml of 1% methylcellulose solution. The plaques were
stained with crystal violet solution after 3 days of incubation at
37°C.
Binding of virus to cells at increased ionic strength of the
medium.
Confluent, dense monolayers of 3-day-old GMK AH1 cells in
24-well plates were precooled for 30 min at room temperature and for 30 min at 4°C. The cells were washed twice with 0.5 ml of cold Hanks
medium supplemented with various concentrations of sodium chloride and
1% BSA (H-NaCl-BSA). Subsequently 0.2 ml of H-NaCl-BSA containing the
same number of relative VP5 units of [3H]thymidine-labeled KOS 321, 333, gC
39,
or gC-neg1 was added. Following adsorption for 20 min at 4°C, the
cells were washed once with 0.5 ml of H-NaCl-BSA and twice with 0.5 ml
of normal Hanks solution. The cells were then lysed with a 5% solution
of sodium dodecyl sulfate and transferred to scintillation vials for
quantification of radioactivity. The binding of nonlabeled virus to
cells was assayed in a similar manner. Briefly, confluent, dense
monolayers of 3-day-old GMK AH1 cells in six-well plates were precooled
for 30 min at room temperature and for 30 min at 4°C. The cells were
washed twice with 2 ml of cold Hanks medium supplemented with various
concentrations of sodium chloride (H-NaCl). Subsequently 1 ml of H-NaCl
containing approximately 200 PFU of an HSV strain was added and left
for adsorption for 20 min at 4°C. The cells were washed once with 2 ml of H-NaCl and twice with 2 ml of normal Hanks solution. The cells
were then overlaid with 1% methylcellulose solution and incubated for
2 (HSV-2 strains) or 3 (HSV-1 strains) days at 37°C for the
development of viral plaques.
 |
RESULTS |
HS-binding capabilities of purified gC and gB homologs of HSV and
purified HSV virions.
To study the relative contribution of gC and
gB homologs for HSV-1 and HSV-2 attachment to cells, the physical
abilities of gC and gB proteins to bind isolated HS receptor molecules
were first assayed. Electrophoretic profiles of the viral proteins used
are shown in Fig. 1. The presence of two
extra bands (ca. 45 and 55 kDa) in the preparation of gB-2 might be
explained by the fact that up to 30% of mature gB-2 (110 kDa) could be
cleaved during in vitro processing. However, due to the presence of
disulfide bonds between Cys1-Cys8 and Cys2-Cys7, these two parts were
purified together by immunoaffinity chromatography but separated when
electrophoresed under reducing conditions (36). To compare
the HS-binding capabilities of gB-1, gB-2, gC-1, and gC-2 (purified
from infected BHK cells), stocks of purified proteins were diluted to
the same protein contents and then mixed with GMK AH1 cell-specific
35S-labeled HS (Fig. 2A).
Purified gB-1 and gB-2 bound similar amounts of HS. The same was
observed for gC-1 and gC-2. Based on these results, the HS-binding
capacity of gB and gC homologs, i.e., the quantity of
35S-HS per molecule of the protein, was calculated. At low
protein concentration, i.e., 0.2 µg, gB-1 bound 1.26 × 10
10, gB-2 bound 1.00 × 10
10, gC-1
bound 4.28 × 10
10, and gC-2 bound 3.54 × 10
10 cpm of HS per protein molecule. The corresponding
values calculated for a high protein concentration, i.e., 5 µg, were
as follows: 6.19 × 10
11 cpm of HS per gB-1
molecule, 6.51 × 10
11 per gB-2 molecule, 4.6 × 10
11 per gC-1 molecule, and 4.27 × 10
11 per gC-2 molecule. These results indicated that at a
relatively low protein concentration, gB homologs bound three to four
times less HS per molecule than gC proteins, whereas at a high protein concentration, gB-1 and gB-2 bound more HS per molecule than gC-1 and
gC-2. To examine whether biological functions of viral glycoproteins could be affected by the cell substratum used for virus multiplication, one of the glycoproteins used, gC-2, was also extracted from HEp-2 and
GMK AH1 cells. The electrophoretic mobility of gC-2 extracted from
HEp-2 cells was comparable to that shown in Fig. 1 for BHK cell-derived
gC-2, whereas the apparent molecular mass of gC-2 purified from GMK AH1
cells was ca. 2 to 3 kDa less than those of two other preparations of
gC-2 (data not shown). gC-2 derived from HEp-2 cells bound slightly
more HS than the corresponding protein extracted from BHK cells (Fig.
2A). In addition, at a concentration of 5 µg, gC-2 purified from GMK
AH1 and HEp-2 cells bound comparable amounts of HS.

View larger version (103K):
[in this window]
[in a new window]
|
FIG. 1.
Electrophoretic analysis of affinity-purified gB-1,
gB-2, gC-1, and gC-2. Glycoproteins were subjected to electrophoresis
under reducing conditions on a 10% acrylamide tris-glycine precast gel
and stained with a colloidal Coomassie blue kit.
|
|

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 2.
(A) HS-binding capabilities of purified gB-1, gB-2,
gC-1, and gC-2. 35S-labeled HS from GMK AH1 cells was
incubated for 2 h at room temperature with purified viral
proteins. Bound HS was trapped on nitrocellulose filters. Values shown
are averages of four individual determinations from two separate
experiments. Data for gC-2 (HEp-2) and the rest of the proteins were
obtained in experiments done at different times. (B) Binding of
purified gB-1, gB-2, gC-1, and gC-2 to HS in the presence of increasing
concentrations of sodium chloride. Purified proteins were incubated
with 35S-labeled HS from GMK AH1 in phosphate buffer
supplemented with specific concentrations of sodium chloride. The rest
of the procedure was as described for panel A. Values shown are
averages of two individual determinations from two separate
experiments.
|
|
Differences in the HS-binding capacities of gB and gC molecules
observed at various protein concentrations inspired us to
investigate
the effect of increased sodium chloride concentration
on binding of
purified proteins to HS (Fig.
2B). This assay is
a measure of
specificity and reflects the relative contribution
of electrostatic
forces to the formation of protein-HS complexes
(see the introduction).
The concentrations of sodium chloride
that reduced the binding of viral
proteins to HS by 50% were 0.18
M for gB-2, 0.19 M for gB-1, 0.23 M
for gC-1, and 0.27 M for gC-2.
These data indicated that there was a
greater contribution of
relatively nonspecific electrostatic forces for
binding of gB
homologs than gC molecules. This could, at least in part,
explain
the differences in the HS-binding capacity of gB molecules when
tested at relatively low and high concentrations of
protein.
In addition to examining HS-binding abilities of gB and gC homologs, we
compared purified, whole HSV-1 and HSV-2 virions for
this ability.
Based on the VP5 contents in different HSV-1 and
HSV-2 preparations,
stocks of purified virus were adjusted to
contain the same relative
number of virus particles and then tested
for the ability to bind GMK
AH1 cell-specific and HEp-2 cell-specific
35S-labeled HS
(Table
1). HSV-1 virions bound more GMK
AH1 cell-specific
HS than HSV-2 particles. The same was observed when
HEp-2 cell-specific
HS was used. In addition, we were interested in
whether differential
binding of HS by HSV-1 and HSV-2 virions could be
related to HSV
type-specific differences that affect their sensitivity
to polyanions.
It was reported (
19) that many different
polyanionic substances
such as heparin, dextran sulfate, agar
inhibitors, or dermatan
sulfate inhibited HSV-2 infection of cells more
efficiently than
HSV-1 infection of cells. We sought to examine whether
this observation
could be extended to a biologically important
polyanionic ligand
for HSV, HS. To this end, two different preparations
of HS, from
human aorta (a gift from W. Murphy, Melbourne, Australia)
and
from bovine kidney (Seikagaku, Tokyo, Japan), were tested for
the
ability to inhibit HSV-1 and HSV-2 infection of GMK AH1 cells.
Virus
adsorption to cells in the presence of exogenously added
HS was carried
out at 4°C. IC
50s of human aorta HS were 20 and
3 µg/ml
for HSV-1 and HSV-2, respectively. The corresponding values
for bovine
kidney HS were >500 and 70 µg/ml for HSV-1 and -2,
respectively.
Thus, as was observed for other polyanions (
19),
less HS was
necessary to inhibit HSV-2 than HSV-1 infection of
cells. This
difference could, at least in part, be attributed
to our observation
that HSV-2 virions bound less HS than HSV-1
particles (Table
1).
Knowing that the binding of viral gB-1, gB-2, gC-1, and gC-2 to HS
molecules was prevented by different concentrations of
sodium chloride,
we sought to determine whether the binding of
whole virus particles to
cells would be affected similarly by
the increased ionic strength of
the medium. To this end, purified
radiolabeled virions of HSV-1 KOS
321, HSV-1 gC

39, HSV-2 333, and HSV-2 gC-neg1 were
compared for the ability
to attach to cells in the presence of
increasing concentrations
of sodium chloride. It should be noted that
this experiment required
exposure of cells to hypertonic concentrations
of sodium chloride.
To protect the cells, all experiments were
conducted at 4°C, and
the total exposure of cells to increased
concentrations of sodium
chloride did not exceed 40 min. Further growth
of GMK AH1 cells
was not affected by this treatment. The concentration
of sodium
chloride necessary to prevent the binding of HSV-2 gC-neg1 by
50% was 0.24 M (Fig.
3A). The corresponding values were 0.27 M
for
HSV-1 gC

39, 0.34 M for HSV-1 KOS 321, and 0.58 M for
HSV-2 333. Similar
tendencies were observed with nonlabeled virus
preparations (Fig.
3B). In this
experiment, following virus adsorption to cells at
4°C in the
presence of sodium chloride, the cells were washed
and incubated at
37°C for viral plaques to develop. Differences
shown in Fig.
3 cannot
be attributed to a direct virus inactivation
by hypertonic solutions of
sodium chloride because incubation
of HSV-1 KOS 321 for 15 min at 4°C
in 0.9 M sodium chloride and
subsequent restoration of isotonicity did
not reduce viral infectivity.
These results indicated that a hierarchy
of sensitivity of virus
binding to increased ionic strength of the
medium, i.e., HSV-2
gC-neg1 > HSV-1 gC

39 > HSV-1 KOS 321 > HSV-2 333, correlated with corresponding
sensitivities of purified viral proteins, i.e., gB-2 > gB-1 >
gC-1 > gC-2 (compare Fig.
2B with Fig.
3).

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 3.
HSV binding to cells in the presence of increasing
concentrations of sodium chloride. Purified radiolabeled (A) or
nonlabeled (B) HSV-1 KOS 321, HSV-1 gC 39, HSV-2 333, and
HSV-2 gC-neg1 were incubated with GMK AH1 cells for 20 min at 4°C in
the presence specific concentrations of sodium chloride. Experiments
were carried out at 4°C (cold room). Sodium chloride solutions were
left on cells for a maximum of 40 min. For further details, see
Materials and Methods. Values shown are averages of four individual
determinations from two separate experiments.
|
|
In an attempt to explain the less efficient binding of HS by HSV-2 than
HSV-1 virions, we considered the possibility that
due to differences in
presentation of protein in its purified
versus virion-associated form,
some glycans may differently modulate
the binding of HS in these two
systems. To this end, purified
gC proteins were treated with
neuraminidase, neuraminidase and
O-glycanase, and
endoglycosidase F/N and then tested for binding
of HS. Electrophoretic
mobility and HS-binding capabilities of
enzyme-treated proteins are
shown in Fig.
4. Although we are aware
that some sugar residues might not be eliminated by these treatments,
removal of terminal sialic acid residues slightly increased HS-binding
capabilities of gC-1 and gC-2, whereas further removal of a population
of
O-glycans specifically cleaved by
O-glycanase
had little or
no effect. In contrast, endoglycosidase F/N-treated gC-1
and gC-2
bound ca. 40 to 50% less HS than untreated controls. Because
neuraminidase-treated
proteins exhibited slightly enhanced HS-binding
capabilities,
we examined the possibility that sialic acid may shield
the binding
of HS by HSV-2 virions. Neuraminidase-treated and
mock-treated
HSV-1 virions bound 24.1% ± 1.9% and 20.9% ± 1.7% of
applied HS,
respectively; the corresponding values for HSV-2 virions
were
7.7% ± 0.7% and 5.6% ± 0.6%. Thus, as was found with
purified
proteins (Fig.
4B), HS-binding capabilities of HSV-1 and HSV-2
virions were only slightly augmented by neuraminidase treatment.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 4.
Carbohydrate modification and HS binding by gC-1 and
gC-2. (A) Electrophoretic analysis of mock (M)-, sialidase (S)-,
sialidase and O-glycanase (SO)-, and endoglycosidase F/N
(N)-treated gC-1 and gC-2. Sizes are indicated in kilodaltons. (B)
Binding of HS by sialidase and/or glycosidase-treated gC-1 and gC-2.
Results are expressed as percent bound HS relative to mock-treated
controls. For further details, see the legend to Fig. 2A.
|
|
It was reported (
10) that wild-type HSV-2 and a gC-null
mutant did not differ in their binding to cells, and consequently
gB-2
was suggested as a dominant HSV-2 attachment protein. Our
data suggest
that gC-2 mediated binding of HSV-2 virions that,
at least to some
extent, appeared to be resistant to increased
ionic strength. To
further explore the extent of manifestation
of gC-2 functions in the
HSV-2 background, HSV-2 wild-type and
gC-neg1 mutant strains were
compared for the ability to form plaques
on heparinase-treated GMK AH1
cells. With HSV-1, we invariably
observed that when assayed on cells
that had been pretreated with
relatively low doses of heparinase, the
gC-null mutant produced
fewer plaques than the wild-type strain (Fig.
5A). This suggested
that gC-1 can
facilitate virus binding when the density of the
HS receptor is
reduced. As seen in Fig.
5B, the same was observed
for the HSV-2
gC-negative mutant and its wild-type parent. This
difference suggests
that at least under these specific conditions,
the presence of gC-2 is
beneficial for HSV-2 virions.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 5.
Infection of heparinase-treated cells by HSV wild-type
and gC-negative mutant strains. GMK AH1 cells in six-well plates cells
were pretreated with the indicated number of heparinase Sigma units (1 IU corresponds to approximately 600 Sigma units) and then approximately
200 PFU of KOS 321, gC 39, or 333 or gC-neg1 was added.
Values shown for HSV-2 are means of six replicates from three separate
experiments. For HSV-1, the results represent means of two replicates
from a single experiment.
|
|
Interaction of gB and gC homologs with cell surface.
In
addition to examining a direct binding of purified proteins to isolated
HS chains, we attempted to search for individual specificities in
interactions of these proteins with the cell surface. To this end, we
tested the effects of selectively or preferentially N-, 2-O-, and
6-O-desulfated preparations of heparin on binding of purified gB-1,
gB-2, gC-1, and gC-2 to GMK AH1 cells (Fig.
6B); similar experiments with whole HSV-1
and HSV-2 were also carried out (Fig. 6A). Compositional analysis of
the products of N- and 2-O-desulfation of heparin revealed selective
removal of N- and 2-O-sulfate groups,
respectively (7). In contrast, 6-O-desulfation is a
preferential process since in addition to 6-O-sulfate
groups, approximately 20 to 30% of 2-O-sulfates are lost.
We reasoned that if the sulfate group of a particular type is
nonessential for interaction, then its selective removal would impair
little or not at all the ability of such modified heparin to compete
with cell surface HS for binding to the isolated viral proteins or
whole virions. In line with this interpretation, ratios of
IC50 of modified heparin to native heparin were calculated for each sample (Table 2). These ratios
were higher for gB-1 than gB-2, suggesting that N-,
2-O-, and 6-O-sulfate groups of heparin could be
more important for interaction with gB-1 than gB-2, or that the latter
could show preference for any two types of sulfates. Little differences
were observed between gC-1 and gC-2 (Fig. 6; Table 2). However, an
overall pattern of sensitivity to modified heparins of gC homologs was
different from that of gB molecules. In particular, less heparin
(determined as IC50) was needed to inhibit gB than gC
binding; however, a significant proportion of binding of gB to cells
was insensitive to heparin. In addition, we found some similarities
between gB-2 and whole HSV-2 (with binding step at 4°C) patterns of
sensitivity to modified heparins (similar IC50s and
incomplete inhibition of binding). Thus, our results suggest that all
three kinds of sulfate groups played a role in interaction with both
types of HSV in the order of significance 2-O-sulfates = 6-O-sulfates > N-sulfates. Because IC50 ratios of modified heparins to native heparin were
higher for HSV-1 than HSV-2, it is likely that 6-O-,
2-O-, and to some extent N-sulfate groups could
be more important for interaction with HSV-1 than HSV-2 (Table 2). A
similar observation regarding these two viruses was made earlier by
others (13).

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 6.
Sensitivities of HSV-1, HSV-2, and purified gC
and gB homologs to selectively desulfated heparin compounds. (A) HSV-1
and HSV-2 were preincubated for 10 min at either 4 or 37°C in the
presence of fivefold-increasing concentrations of N-, 2-O-, or
6-O-desulfated samples of heparin. Mixtures were transferred to GMK AH1
cells and held for 1 h at either 4 or 37°C. The number of PFU is
expressed as a percentage of the average number of plaques formed in
the absence of competitor. Two to three separate experiments were
carried out in duplicate for each sample. (B) Purified gB-1, gB-2,
gC-1, and gC-2 were preincubated for 10 min at 4°C in the presence of
10-fold-increasing concentrations of modified heparin samples. The
mixtures were transferred to GMK AH1 cells in 96-well plates and left
for attachment for 1 h at 4°C. Bound glycoproteins were detected
by an ELISA-based procedure. Results are means of six replicates from
two separate experiments.
|
|
 |
DISCUSSION |
A number of type-specific differences have been reported for
the early interaction of HSV-1 and HSV-2 with cells. In addition to
having distinct preferential tropisms, these two viruses differ in
their sensitivity to polyanions (19) and polycations
(24, 25), preference for specific structural features of
HS/heparin chains (13), binding to the C3b component of
complement (8), and stimulation of viral infection in
glycosaminoglycan-deficient cells by dextran sulfate (5). In
the present investigation, we observed another type-specific
difference: purified HSV-2 virions bound fewer isolated HS molecules
than HSV-1 virions. Because the structures of HS chains produced in
particular cells are thought to be similar (for a review, see reference
40), it is likely that physical abilities to bind HS
are greater for HSV-1 than HSV-2. However, the possibility that
decreased binding of HS by HSV-2 could be attributed to the affinity of
the virus for some rare structural features of HS chains cannot be
excluded. In addition, the binding experiments in the presence of
increased ionic strength revealed that the binding of HSV-1 to cells is
more dependent on relatively nonspecific electrostatic forces than the
attachment of HSV-2 virions. gC-2 appeared to mediate this
characteristic binding of HSV-2 to cells. The binding of HSV
gC-negative mutants as well as that of their putative attachment
proteins, (gB homologs) was found to rely on a substantial contribution
of electrostatic forces. Such the binding is known to be critically
dependent on the ligand concentration, a feature that may explain
decreased infectivity of the gC-negative mutant on heparinase-treated
cells or efficient binding of HS by gB homologs that occurred only at a
high concentration of protein.
In addition, our data could provide an explanation of other HSV
type-specific phenotypes, especially those associated with greater
sensitivity to polyanions of HSV-2 than of HSV-1. Because a likely
mechanism of virus-HS interaction is binding of negatively charged
sulfate/carboxylate groups of HS chains to positively charged
HS-binding domains in the viral envelope glycoprotein gC and/or gB, our
results suggest some basic differences in an overall positive charge or
a distribution of charges on the surfaces of HSV-1 and HSV-2. In a
viral plaque assay, we observed that HSV-2 was more sensitive than
HSV-1 to different HS preparations. Hutton et al. (19) found
that HSV-2 strains were more sensitive than HSV-1 strains to several
polyanionic substances of carbohydrate nature such as heparin, dextran
sulfate, and dermatan sulfate. This type-specific difference could, at
least in part, be related to our observation that HSV-2 virions bound
less HS than did HSV-1 virions. Thus, irrespective of the competition
capacity of a particular compound, less HS or other polyanions might be
necessary to saturate or block the HS-binding sites on the HSV-2 than
on the HSV-1 virion surface.
Both gB and gC molecules of the virus envelope could mediate
binding to HS (10, 14, 15). To understand the relative contribution of gB and gC for HSV attachment to cells, we tested the
binding of purified gB-1, gB-2, gC-1, and gC-2 to isolated HS receptor
molecules. gB-1 and gB-2 did not differ with respect to the amount of
HS bound. Similarly, gC-1 and gC-2 bound comparable amounts of HS (the
HEp-2 cell-extracted gC-2 bound slightly more HS than gC-1); however,
these proteins exhibited greater HS-binding capacities than gB homologs
when tested at a relatively low concentration of protein.
Interestingly, even though the potentials to bind to HS were similar
for gB homologs and for the gC homolog, purified HSV-1 virions, as
noted before, bound more HS than HSV-2 virions. Similar observations on
the binding of the C3b component of complement by purified viral
components and by HSV-infected cells were made earlier by others
(6, 8, 34). While purified gC-1 and gC-2 bound C3b
efficiently (6), HSV-1-infected but not HSV-2-infected cells
exhibited this activity (8). These data together with the
observation that the gC-2-negative HSV-2 mutant bound to cells as
efficiently as the wild-type gC-2-positive strain (10)
suggest that HS- and C3b-binding potentials of gC-2 are not fully
exhibited when this protein is present in the HSV-2 background. In
contrast to HSV-2-infected cells, transfected cells expressing gC-2 on their surfaces bound C3b efficiently, suggesting that an HSV-2-specific protein(s) may shield and/or interact with gC-2, thus reducing its
functions, although induction of C3b receptor as a result of relative
overexpression of gC-2 on transfected cells compared to virus-infected
cells cannot be excluded (41).
In our attempt to explain the reduced binding of HS by HSV-2
virions compared to HSV-1 particles, we focused on the structural differences between gC-1 and gC-2. In gC-1, a major part of the HS-binding domain was localized around the base of a small
amino-terminal Cys127-Cys144 loop (39) and was found to
comprise several positively charged amino acids scattered between
residues 129 through 160 (51; K. Mårdberg, E. Trybala, J. C. Glorioso, and T. Bergström, submitted for
publication). Positively charged amino acids in the gC-1 segment
delimited by Lys114 and Asp128 can also contribute to the virus binding
to cells (49; Mårdberg et al., submitted). An
entire gC-1 segment that is located N terminally to the HS-binding domain (amino acids 26 through 113) represents in fact a mucin-like region with 22 predicted O-glycosylation (12) and 5 N-glycosylation (9) sites. Of these, no more than 13 O-glycosylation sites and at least 4 N-glycosylation sites are occupied
in baculovirus-expressed gC-1 (39). The HS-binding domain of
gC-2 has not been localized. However, by analogy to gC-1, positively
charged amino acids scattered around the base of Cys96-Cys113 loop, and
a cluster of basic residues between Arg66 and Lys72 are likely
candidates. In contrast to gC-1, the N-terminal part of gC-2 may not
possess the mucin-like structure (39), as in this region
there are only four predicted O-glycosylation sites (12),
and none of them were detected to be occupied in baculovirus-expressed
gC-2 (39). Instead, positively charged amino acids are
scattered throughout the N-terminal part of gC-2 (48). With
these differences in mind, we tested how different glycans would modify
HS-binding abilities of gC-1 and gC-2. Although electrophoretic
analysis suggested that gC-2 might contain more sialic acid residues
than gC-1, removal of this sugar had only a slight enhancing effect on
the binding of HS by both gC-1 and gC-2. Similarly,
neuraminidase-treated HSV-2 virions bound only slightly more HS
molecules than the sham-treated virions, suggesting that sialic acid
was not the factor that markedly masked this activity in HSV-2 virions.
It was reported that neuraminidase treatment of either HSV-1-infected
cells (44) or purified gC-1 and gC-2 (6)
substantially enhanced binding of complement component C3b. This
treatment, however, did not unmask C3b receptor on HSV-2-infected cells
(44). Further, we found that O-glycanase
treatment had little or no effect on HS binding by gC-1 and gC-2,
whereas removal of N-glycans decreased binding activity by
40 to 50%. Similar results were reported for studies on the effect of
removal of these glycans on binding of gC-1 to cells (49).
As no enhancing effects were observed, it is unlikely that either O- or
N-linked glycans of gC-2 could down-modulate the binding of HS by HSV-2 virions. However, apart from modulation of biological activities, the
mucin-like domains may influence the structure of a protein. Thus, one
can speculate that due to absence of a mucin-like region in gC-2, this
protein may not adopt a long and slender morphology as was reported for
gC-1 (45), a structural feature that could affect its
attachment functions. In addition, one cannot exclude that the
N-terminal part of gC-2 could be a target for nonspecific interactions
due to the presence of multiple basic amino acids (calculated
isoelectric points for gC-2 and gC-1 are 10.34 and 7.48, respectively).
In this regard, either expression of a limited number of gC-2 copies or
occurrence of gC-2 in complexes with other HSV-2 proteins could be of
benefit. Thus, differences in presentation and/or quantity of gC copies
in the virus envelope may account for the reduced binding of HS by
HSV-2 virions compared to HSV-1 particles.
In this study, we observed that HSV-1 and HSV-2 virions differed
with respect to the quantity of HS chains bound. Herold et al.
(13) observed some qualitative differences between
susceptibility of HSV-1 and HSV-2 to modified heparin compounds. HSV-1
appeared to be less sensitive than HSV-2 to O-desulfated heparin
preparations, suggesting that 2-O- and
6-O-sulfate groups of heparin or HS are important
determinants for interaction with HSV-1 (13). Here we
confirmed this observation and extended this approach to compare the
abilities of selectively N-, 2- O-, and 6-O-desulfated heparin preparations to inhibit binding to cells of purified gB-1, gB-2, gC-1,
and gC-2. As noted before, O-sulfate groups of heparin
appeared to be more important for interaction with gB-1 than gB-2. In
addition the patterns of sensitivity to modified heparins of gB
homologs were distinct from those of gC proteins. This finding,
together with the observation that gB homologs bound fewer HS than gC
molecules, suggests that these proteins may contribute different
functions in early virus-cell interaction. Presumably these functions
are balanced differently in the two types of HSV. Given the presence in
the HSV-1 envelope of approximately 3,200 and 4,900 copies of gB-1 and
gC-1, respectively (11), and the length of HS chains exceeding 40 nm, multiple gC-1 and gB-1 molecules are likely to interact with single HS chain. It is noteworthy that gB, gC, and another HSV-1 protein gD were reported to function as oligomeric complexes in the virus envelope (11). It has recently been
reported that in addition to gB and gC, gD-1 bound HS chains that had
been modified by 3-O-sulfotransferase isoform 3 and
that this event triggered HSV-1 entry into CHO cells (43).
Prior gC- and/or gB-mediated immobilization of HS chains on the
virus surface may help gD recognize the specific binding site on the chain.
 |
ACKNOWLEDGMENTS |
We thank Dorothe Spillmann (Uppsala University, Uppsala, Sweden)
for modified heparin compounds and Gary Cohen and Roselyn Eisenberg
(University of Pennsylvania) for polyclonal rabbit sera.
This work was supported by grants (all to T.B.) from the Stiftelsen
för Strategisk Forskning "Glycoconjugates in Biological Systems," Swedish Medical Research Council (no. 11225), Sahlgren's University Hospital Läkarutbildningsavtal, and Scandinavian
Society for Antimicrobial Chemotherapy.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Clinical Virology, Göteborg University, Guldhedsgatan 10B, S-413
46 Göteborg, Sweden. Phone: 46-31-604735. Fax: 46-31-827032. E-mail: tomas.bergstrom{at}microbio.gu.se.
 |
REFERENCES |
| 1.
|
Bergström, T.,
E. Sjögren-Janson,
S. Jeansson, and E. Lycke.
1992.
Mapping neuroinvasiveness of the herpes simplex virus type 1 encephalitis-inducing strain 2762 by the use of monoclonal antibodies.
Mol. Cell. Probes
6:41-49[CrossRef][Medline].
|
| 2.
|
Camdadelli-Fiume, G.,
D. Stripe,
A. Boscaro,
E. Avitable,
L. Foa-Tomasi,
D. Barker, and B. Roizman.
1990.
Glycoprotein C-dependent attachment of herpes simplex virus to susceptible cells leading to productive infection.
Virology
178:213-222[CrossRef][Medline].
|
| 3.
|
Danishefsky, I., and H. Steiner.
1965.
Investigations on the chemistry of heparin. V. Disaccharides obtained after partial hydrolysis.
Biochim. Biophys. Acta
101:37-45[Medline].
|
| 4.
|
Duff, R., and F. Rapp.
1971.
Oncogenic transformation of hamster cells after exposure to herpes simplex virus type 2.
Nat. New Biol.
233:48-50[CrossRef][Medline].
|
| 5.
|
Dyer, A. P.,
B. W. Banfield,
D. Martindale,
D.-M. Spannier, and F. Tufaro.
1997.
Dextran sulfate can act as an artificial receptor to mediate a type-specific herpes simplex virus infection via glycoprotein B.
J. Virol.
71:191-198[Abstract].
|
| 6.
|
Eisenberg, R. J.,
M. Ponce de Leon,
H. M. Friedman,
L. Fries,
M. M. Frank,
J. Hastings, and G. H. Cohen.
1987.
Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus type 1 and 2.
Microb. Pathog.
3:423-425[CrossRef][Medline].
|
| 7.
|
Feyzi, E.,
E. Trybala,
T. Bergström,
U. Lindahl, and D. Spillmann.
1997.
Structural requirement of heparan sulfate for interaction with herpes simplex type 1 virions and isolated glycoprotein C.
J. Biol. Chem.
272:24850-24857[Abstract/Free Full Text].
|
| 8.
|
Friedman, H. M.,
G. H. Cohen,
R. J. Eisenberg,
C. Seidel, and D. B. Cines.
1984.
Glycoprotein C of herpes simplex virus type 1 acts as a receptor for C3b component of complement on infected cells.
Nature
309:633-635[CrossRef][Medline].
|
| 9.
|
Frink, R. J.,
R. J. Eisenberg,
G. H. Cohen, and E. K. Wagner.
1983.
Detailed analysis of the portion of the herpes simplex virus type 1 genome encoding glycoprotein C.
J. Virol.
45:634-647[Abstract/Free Full Text].
|
| 10.
|
Gerber, S. I.,
B. J. Belval, and B. C. Herold.
1995.
Differences in the role of glycoprotein C of HSV-1 and HSV-2 in viral binding may contribute to serotype differences in cell tropism.
Virology
214:29-39[CrossRef][Medline].
|
| 11.
|
Handler, C. G.,
R. J. Eisenberg, and G. H. Cohen.
1996.
Oligomeric structure of glycoproteins in herpes simplex virus type 1.
J. Virol.
70:6067-6075[Abstract].
|
| 12.
|
Hansen, J. E.,
O. Lund,
J. Engelbrecht,
H. Bohr,
J. O. Nielsen, and J. E. Hansen.
1995.
Prediction of O-glycosylation in mammalian proteins: specificity patterns of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase.
Biochem. J.
308:801-813.
|
| 13.
|
Herold, B. C.,
S. I. Gerber,
B. J. Belval,
A. M. Siston, and N. Shulman.
1996.
Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry.
J. Virol.
70:3461-3469[Abstract].
|
| 14.
|
Herold, B. C.,
D. WuDunn,
N. Soltys, and P. G. Spear.
1991.
Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity.
J. Virol.
65:1090-1098[Abstract/Free Full Text].
|
| 15.
|
Herold, B. C.,
D. WuDunn,
R. J. Visalli,
N. Sumarski,
C. Brandt, and P. G. Spear.
1994.
Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface heparan sulfate and glycoprotein B.
J. Gen. Virol.
75:1211-1222[Abstract/Free Full Text].
|
| 16.
|
Holland, T. C.,
F. L. Homma,
S. D. Marlin,
M. Levine, and J. Glorioso.
1984.
Herpes simplex virus type 1 glycoprotein C-negative mutants exhibit multiple phenotypes, including secretion of truncated glycoproteins.
J. Virol.
52:566-574[Abstract/Free Full Text].
|
| 17.
|
Holland, T. C.,
S. D. Marlin,
M. Levine, and J. Glorioso.
1983.
Antigenic variants of herpes simplex virus selected with glycoprotein-specific monoclonal antibodies.
J. Virol.
45:672-682[Abstract/Free Full Text].
|
| 18.
|
Homma, F. L.,
D. J. M. Purifoy,
J. C. Glorioso, and M. Levine.
1986.
Molecular basis of glycoprotein C-negative phenotypes of herpes simplex virus type 1 mutants selected with a virus-neutralizing monoclonal antibody.
J. Virol.
58:281-289[Abstract/Free Full Text].
|
| 19.
|
Hutton, R. D.,
D. L. Ewert, and G. R. French.
1973.
Differentiation of types 1 and 2 of herpes simplex virus by plaque inhibition with sulfated polyanions.
Proc. Soc. Exp. Biol. Med.
142:27-29[CrossRef][Medline].
|
| 20.
|
Inoue, Y., and K. Nagasawa.
1976.
Selective N-desulfation of heparin with dimethyl sulfoxide containing water or methanol.
Carbohydr. Res.
46:87-95[CrossRef][Medline].
|
| 21.
|
Jaseja, M.,
R. N. Rej,
F. Sauriol, and A. Perlin.
1989.
Novel regio- and stereoselective modifications of heparin in alkaline solution. Nuclear magnetic resonance spectroscopic evidence.
Can. J. Chem.
67:1449-1456[CrossRef].
|
| 22.
|
Jeansson, S., and L. Molin.
1974.
On the occurrence of genital herpes simplex virus infection. Clinical and virological findings and relation to gonorrhoea.
Acta Dermatol. Venereol.
54:479-485[Medline].
|
| 23.
|
Karger, A., and T. C. Mettenleiter.
1993.
Glycoproteins gIII and gp50 play a dominant roles in the biphasic attachment of pseudorabies virus.
Virology
194:654-664[CrossRef][Medline].
|
| 24.
|
Langeland, N.,
L. J. Moore,
H. Holmsen, and L. Haarr.
1988.
Interaction of polylysine with the cellular receptor for herpes simplex virus type 1.
J. Gen. Virol.
69:1137-1145[Abstract/Free Full Text].
|
| 25.
|
Langeland, N.,
A. L. J. Moore,
J. R. Lillehaug, and L. Haarr.
1987.
Evidence that neomycin inhibits binding of herpes simplex virus type 1 to cellular receptor.
J. Virol.
61:3388-3393[Abstract/Free Full Text].
|
| 26.
|
Langeland, N.,
A. M. Oyan,
H. S. Marsden,
A. Cross,
J. C. Glorioso,
L. Moore, and L. Haarr.
1990.
Localization on the herpes simplex virus type 1 genome of a region encoding proteins involved in adsorption to cellular receptor.
J. Virol.
64:1271-1277[Abstract/Free Full Text].
|
| 27.
|
Lindahl, U.,
J. A. Cifonelli,
B. Lindahl, and L. Rodén.
1965.
The role of serine in the linkage of heparin to protein.
J. Biol. Chem.
240:2817-2820[Free Full Text].
|
| 28.
|
Lloyd, A. G.,
G. Embery, and L. J. Fowler.
1971.
Studies on heparin degradation. I. Preparation of [35S]sulphamate derivatives for studies on heparin degrading enzymes of mammalian origin.
Biochem. Pharmacol.
20:637-648[CrossRef][Medline].
|
| 29.
|
Lycke, E.,
M. Johansson,
B. Svennerholm, and U. Lindahl.
1991.
Binding of herpes simplex virus to cellular heparan sulphate, an initial step in the adsorption process.
J. Gen. Virol.
72:1131-1137[Abstract/Free Full Text].
|
| 30.
|
Lyon, M.,
J. A. Deakin,
K. Mizuno,
T. Nakamura, and J. T. Gallagher.
1994.
Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants.
J. Biol. Chem.
269:11216-11223[Abstract/Free Full Text].
|
| 31.
|
Maccarana, M., and U. Lindahl.
1993.
Mode of interaction between platelet factor 4 and heparin.
Glycobiology
3:271-277[Abstract/Free Full Text].
|
| 32.
|
Manning, G. S.
1978.
The molecular theory of polyelectrolyte solutions with applications to the electrostatic properties of polynucleotides.
Q. Rev. Biophys.
11:179-246[Medline].
|
| 33.
|
McClain, D. S., and A. O. Fuller.
1994.
Cell-specific kinetics and efficiency of herpes simplex virus type 1 entry are determined by two distinct phases of attachment.
Virology
198:690-702[CrossRef][Medline].
|
| 34.
|
McNearney, T. A.,
C. Odell,
V. M. Holers,
P. G. Spear, and J. P. Atkinson.
1987.
Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity.
J. Exp. Med.
166:1525-1535[Abstract/Free Full Text].
|
| 35.
|
Nagasawa, K.,
Y. Inoue, and T. Kamata.
1977.
Solvolytic desulfation of glycosaminoglycuronan sulfates with dimethyl sulfoxide containing water or methanol.
Carbohydr. Res.
58:47-55[CrossRef][Medline].
|
| 36.
|
Norais, N.,
D. Tang,
S. Kaur,
S. H. Chamberlain,
F. R. Masiarz,
R. L. Burke, and F. Marcus.
1996.
Disulfide bonds of herpes simplex virus type 2 glycoprotein gB.
J. Virol.
70:7379-7387[Abstract].
|
| 37.
|
Oyan, A. M.,
K. E. Dolter,
N. Langeland,
W. F. Goins,
J. C. Glorioso,
L. Haarr, and C. S. Crumpacker.
1993.
Resistance of herpes simplex virus type 2 to neomycin maps to N-terminal portion of glycoprotein C.
J. Virol.
67:2434-2441[Abstract/Free Full Text].
|
| 38.
|
Robbins, A. K.,
D. J. Dorney,
M. W. Wathen,
M. E. Whealy,
C. Gold,
R. J. Watson,
L. E. Holland,
S. E. Weed,
M. Levine,
J. C. Glorioso, and L. W. Enquist.
1987.
The pseudorabies virus gII gene is closely related to the gB glycoprotein gene of herpes simplex virus.
J. Virol.
61:2691-2701[Abstract/Free Full Text].
|
| 39.
|
Rux, A. H.,
W. T. Moore,
J. D. Lambris,
W. R. Abrams,
C. Peng,
H. M. Friedman,
G. H. Cohen, and R. J. Eisenberg.
1996.
Disulfide bond structure determination and biochemical analysis of glycoprotein C from herpes simplex virus.
J. Virol.
70:5455-5465[Abstract/Free Full Text].
|
| 40.
|
Salmivirta, M.,
K. Lidholt, and U. Lindahl.
1996.
Heparan sulfate: a piece of information.
FASEB J.
10:1270-1279[Abstract].
|
| 41.
|
Seidel-Dugan, C.,
M. Ponce de Leon,
H. M. Friedman,
L. F. Fries,
M. M. Frank,
G. H. Cohen, and R. J. Eisenberg.
1988.
C3b receptor activity on transfected cells expressing glycoprotein C of herpes simplex virus types 1 and 2.
J. Virol.
62:4027-4036[Abstract/Free Full Text].
|
| 42.
|
Shieh, M. T., and P. G. Spear.
1994.
Herpesvirus-induced cell fusion that is dependent on cell surface heparan sulfate or soluble heparin.
J. Virol.
68:1224-1228[Abstract/Free Full Text].
|
| 43.
|
Shukla, D.,
J. Liu,
P. Blaiklock,
N. W. Shworak,
X. Bai,
J. D. Esko,
G. H. Cohen,
R. J. Eisenberg,
R. D. Rosenberg, and P. G. Spear.
1999.
A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus entry.
Cell
99:13-22[CrossRef][Medline].
|
| 44.
|
Smiley, M. L., and H. M. Friedman.
1985.
Binding of complement component C3b to glycoprotein C is modulated by sialic acid on herpes simplex virus type 1-infected cells.
J. Virol.
55:857-861[Abstract/Free Full Text].
|
| 45.
|
Stannard, L. M.,
A. O. Fuller, and P. G. Spear.
1987.
Herpes simplex virus glycoproteins associated with different morphological entities projecting from the virus envelope.
J. Gen. Virol.
68:715-725[Abstract/Free Full Text].
|
| 46.
|
Stuve, L. L.,
S. Brown-Shimer,
C. Pachl,
R. Najarian,
D. Dina, and R. L. Burke.
1987.
Structure and expression of the herpes simplex virus type 2 glycoprotein gB gene.
J. Virol.
61:326-335[Abstract/Free Full Text].
|
| 47.
|
Svennerholm, B.,
S. Jeansson,
A. Vahlne, and E. Lycke.
1991.
Involvement of glycoprotein C (gC) in adsorption of herpes simplex virus type 1 (HSV-1) to cells.
Arch. Virol.
120:273-279[CrossRef][Medline].
|
| 48.
|
Swain, M. A.,
R. W. Peet, and D. A. Galloway.
1985.
Characterization of the gene encoding herpes simplex virus type 2 glycoprotein C and comparison with the type 1 counterpart.
J. Virol.
53:561-569[Abstract/Free Full Text].
|
| 49.
|
Tal-Singer, R.,
C. Peng,
M. Ponce de Leon,
W. R. Abrams,
B. W. Banfield,
F. Tufaro,
G. H. Cohen, and R. J. Eisenberg.
1995.
Interaction of herpes simplex virus glycoprotein gC with mammalian cell surface molecules.
J. Virol.
69:4471-4483[Abstract].
|
| 50.
|
Thompson, L. D.,
M. W. Pantoliano, and B. A. Springer.
1994.
Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain.
Biochemistry
33:3831-3840[CrossRef][Medline].
|
| 51.
|
Trybala, E.,
T. Bergström,
B. Svennerholm,
S. Jeansson,
J. C. Glorioso, and S. Olofsson.
1994.
Localization of a functional site of herpes simplex virus type 1 glycoprotein C involved in binding to cell surface heparan sulfate.
J. Gen. Virol.
75:743-752[Abstract/Free Full Text].
|
| 52.
|
WuDunn, D., and P. G. Spear.
1989.
Initial interaction of herpes simplex virus with cells is binding to heparan sulfate.
J. Virol.
63:52-58[Abstract/Free Full Text].
|
Journal of Virology, October 2000, p. 9106-9114, Vol. 74, No. 19
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kalia, M., Chandra, V., Rahman, S. A., Sehgal, D., Jameel, S.
(2009). Heparan Sulfate Proteoglycans Are Required for Cellular Binding of the Hepatitis E Virus ORF2 Capsid Protein and for Viral Infection. J. Virol.
83: 12714-12724
[Abstract]
[Full Text]
-
de Jong, M. A. W. P., de Witte, L., Bolmstedt, A., van Kooyk, Y., Geijtenbeek, T. B. H.
(2008). Dendritic cells mediate herpes simplex virus infection and transmission through the C-type lectin DC-SIGN. J. Gen. Virol.
89: 2398-2409
[Abstract]
[Full Text]
-
Pinna, D., Oreste, P., Coradin, T., Kajaste-Rudnitski, A., Ghezzi, S., Zoppetti, G., Rotola, A., Argnani, R., Poli, G., Manservigi, R., Vicenzi, E.
(2008). Inhibition of Herpes Simplex Virus Types 1 and 2 In Vitro Infection by Sulfated Derivatives of Escherichia coli K5 Polysaccharide. Antimicrob. Agents Chemother.
52: 3078-3084
[Abstract]
[Full Text]
-
Isaacs, C. E., Wen, G. Y., Xu, W., Jia, J. H., Rohan, L., Corbo, C., Di Maggio, V., Jenkins, E. C. Jr., Hillier, S.
(2008). Epigallocatechin Gallate Inactivates Clinical Isolates of Herpes Simplex Virus. Antimicrob. Agents Chemother.
52: 962-970
[Abstract]
[Full Text]
-
Adamiak, B., Ekblad, M., Bergstrom, T., Ferro, V., Trybala, E.
(2007). Herpes Simplex Virus Type 2 Glycoprotein G Is Targeted by the Sulfated Oligo- and Polysaccharide Inhibitors of Virus Attachment to Cells. J. Virol.
81: 13424-13434
[Abstract]
[Full Text]
-
Uyama, T., Ishida, M., Izumikawa, T., Trybala, E., Tufaro, F., Bergstrom, T., Sugahara, K., Kitagawa, H.
(2006). Chondroitin 4-O-Sulfotransferase-1 Regulates E Disaccharide Expression of Chondroitin Sulfate Required for Herpes Simplex Virus Infectivity. J. Biol. Chem.
281: 38668-38674
[Abstract]
[Full Text]
-
Krey, T., Himmelreich, A., Heimann, M., Menge, C., Thiel, H.-J., Maurer, K., Rumenapf, T.
(2006). Function of Bovine CD46 as a Cellular Receptor for Bovine Viral Diarrhea Virus Is Determined by Complement Control Protein 1.. J. Virol.
80: 3912-3922
[Abstract]
[Full Text]
-
Bergefall, K., Trybala, E., Johansson, M., Uyama, T., Naito, S., Yamada, S., Kitagawa, H., Sugahara, K., Bergstrom, T.
(2005). Chondroitin Sulfate Characterized by the E-disaccharide Unit Is a Potent Inhibitor of Herpes Simplex Virus Infectivity and Provides the Virus Binding Sites on gro2C Cells. J. Biol. Chem.
280: 32193-32199
[Abstract]
[Full Text]
-
Bender, F. C., Whitbeck, J. C., Lou, H., Cohen, G. H., Eisenberg, R. J.
(2005). Herpes Simplex Virus Glycoprotein B Binds to Cell Surfaces Independently of Heparan Sulfate and Blocks Virus Entry. J. Virol.
79: 11588-11597
[Abstract]
[Full Text]
-
Eriksson, K., Bellner, L., Gorander, S., Lowhagen, G.-B., Tunback, P., Rydberg, K., Liljeqvist, J.-A.
(2004). CD4+ T-cell responses to herpes simplex virus type 2 (HSV-2) glycoprotein G are type specific and differ in symptomatic and asymptomatic HSV-2-infected individuals. J. Gen. Virol.
85: 2139-2147
[Abstract]
[Full Text]
-
Selinka, H.-C., Giroglou, T., Nowak, T., Christensen, N. D., Sapp, M.
(2003). Further Evidence that Papillomavirus Capsids Exist in Two Distinct Conformations. J. Virol.
77: 12961-12967
[Abstract]
[Full Text]
-
Pallier, C., Tebourbi, L., Chopineau-Proust, S., Schoevaert, D., Nordmann, P., Testart, J., Courtot, A.-M.
(2002). Herpesvirus, cytomegalovirus, human sperm and assisted fertilization. Hum Reprod
17: 1281-1287
[Abstract]
[Full Text]
-
Mardberg, K., Trybala, E., Tufaro, F., Bergstrom, T.
(2002). Herpes simplex virus type 1 glycoprotein C is necessary for efficient infection of chondroitin sulfate-expressing gro2C cells. J. Gen. Virol.
83: 291-300
[Abstract]
[Full Text]
-
Rue, C. A., Ryan, P.
(2002). Characterization of pseudorabies virus glycoprotein C attachment to heparan sulfate proteoglycans. J. Gen. Virol.
83: 301-309
[Abstract]
[Full Text]